CDKN2A and sarcoma: These results suggest that epigenetic silencing of p16, likely by promoter methylation as observed in DMBA-induced p16+/− lymphomas and sarcomas [12], plays an important role in p16+/−;Brca1MGKO mammary tumorigenesis.